Frontlight ResearchEarly access
CompletedEarly phase 1
Pioglitazone for Idiopathic Gastroparesis
Key facts
- Who runs it
- Johns Hopkins University
- Where
- Baltimore, United StatesSee the site
- Trial code
- Status
- Completed
- Phase
- Early phase 1
- People taking part
- 14 people enrolled
- Started
- 24 Oct 2019
- Ended
- 18 Mar 2025
- Type of study
- Interventional
- Treatments tested
- Pioglitazone 30 mg
- Record updated
- 30 April 2025
Who can take part
- Age
- 18 years and older
- Sex
- Women and men
- Healthy volunteers
- Cannot take part
The registry criteria, word for word
Show all 19 criteriaShow less
Who can take part
- Age 18 years or older at registration
- Diagnosis of gastroparesis as documented by gastric emptying scintigraphy (4-hour emptying after a low-fat meal with any combination of 2 and 4 hour retention of >60% and 10% respectively)
- Ongoing symptoms referable to gastroparesis (i.e. Nausea and vomiting, bloating, and abdominal pain)
- Exclusion of other causes of symptoms such as mechanical gastrointestinal obstruction, uncontrolled esophagitis, peptic ulcer disease, etc. By standard radiographic or endoscopic tests
- Females will be required to use adequate contraceptive methods during study participation as determined by the Principal Investigator and the study team members
Who cannot take part
- Previous surgery of the upper gastrointestinal tract, including vagotomy
- Concurrent use of: estradiol, ethynyl estradiol, mestranol, pazopanib, warfarin, digoxin, atorvastatin, ranitidine, gemfibrozil, fexofenadine, midazolam
- Another active disorder, which could explain symptoms in the opinion of the investigator
- Another active disorder, which could explain symptoms in the opinion of the investigator
- Serious systemic disease, such as recent myocardial infarction/unstable angina, decompensated congestive heart failure, severe pulmonary disease with dyspnea at rest, or altered mental status from any cause
- Contraindications to pioglitazone such as hypersensitivity or allergy
- Any other condition, which in the opinion of the investigator would impede compliance or hinder the completion of the study
- History of bladder cancer or family history of bladder cancer
- Failure to give informed consent
- Significant hepatic injury as defined by significant alanine aminotransferase (ALT) and aspartate aminotransferase (AST) elevations of greater than 2 x upper limit of normal (ULN) or a Child-Pugh score of 10 or greater
- Diabetes as defined by HbA1c >6.5 and/or fasting blood sugar of >125 mg/DL
- Age < than 18 years
- Pregnancy or nursing
- Use of narcotics more than 3 days per week
Where in United States
- Johns Hopkins Bayview Medical CenterBaltimore, United States
About the trial
What the trial wants to find out
The principal objective of this pilot study will be to evaluate whether 8 weeks of treatment of pioglitazone will improve symptoms as measured by the Gastrointestinal Symptom Index (GCSI) in patients with Idiopathic Gastroparesis.
The group in the trial
- PioglitazoneTreatment being tested
Candidates who after the screening period are eligible to receive Pioglitazone
Treatment: Pioglitazone 30 mg
Data and sources
- Registry record
- Listed on ClinicalTrials.gov.How to verify a trial in the registry
- Official title
- Pioglitazone for the Treatment of Idiopathic Gastroparesis (PIOGAS Study)
- Record updated
- 30 April 2025